Clinical Question: In patients receiving therapeutic low-molecular-weight heparin (LMWH), does anti-Xa monitoring with subsequent dose adjustment improve bleeding or thrombotic outcomes?
Background: Anti-Xa monitoring is often used when therapeutic LMWH is prescribed to patients considered at higher risk for altered drug exposure, including those with renal impairment, obesity, pregnancy, advanced age, or cancer. However, practice varies widely, therapeutic target ranges are not standardized across LMWH products, and the relationship between anti-Xa levels and meaningful clinical outcomes has remained uncertain.
Study Design: Systematic review
Setting: Review of international clinical studies of therapeutic subcutaneous LMWH, identified through PubMed, with authors based in the Netherlands
Synopsis: This systematic review included 48 randomized and observational studies involving 6,054 patients receiving therapeutic LMWH, most commonly enoxaparin, across high-risk groups including pregnancy, renal impairment, obesity, older age, and cancer. The intervention was anti-Xa monitoring with subsequent dose adjustment. The primary outcome was whether anti-Xa-guided dosing improved clinical outcomes compared with unmonitored dosing; only five studies directly addressed this question, and bleeding and recurrent thrombosis were similar between monitored and unmonitored groups. Key secondary outcomes were the relationship between anti-Xa levels and bleeding or thrombosis and the frequency of dose adjustment. Anti-Xa levels showed little consistent correlation with clinical events, although monitoring frequently prompted dose changes. Important limitations included substantial heterogeneity in patient populations, LMWH regimens, anti-Xa targets, and sampling methods, along with a uniformly high risk of bias. Overall, the findings support existing guideline uncertainty and do not support routine anti-Xa monitoring during therapeutic LMWH use.
Bottom Line: Current evidence does not support routine anti-Xa monitoring to guide therapeutic LMWH dose adjustment, even in commonly monitored high-risk populations.
Citation: Jaspers TCC, et al. A systematic review on anti-Xa monitoring in the therapeutic use of low-molecular-weight heparins. J Thromb Haemost. 2025;23(10):3033-3055. doi:10.1016/j.jtha.2025.06.025.
Dr. Kulkarni
Dr. Kulkarni is an academic hospitalist in the division of hospital medicine and associate program director of the internal medicine residency program at MedStar Washington Hospital Center, and an assistant professor of medicine at Georgetown University School of Medicine, both in Washington, D.C